Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Objectives: Pompe disease is a progressive metabolic myopathy for which enzyme replacement therapy (ERT) was approved in 2006. While various publications have examined the effects of ERT in classic‐infantile patients and in adults, little has been published on ERT in children with non‐classic presentations. Study design: This prospective study was conducted from June 1999 to May 2015. Seventeen patients from various countries participated. Outcome measures comprised muscle function (6‐minute walk test, quick motor‐function test (QMFT)), muscle strength (hand‐held dynamometry; manual muscle testing), and lung function (FVC sitting and supine). For each outcome measure, we used linear mixed‐effects models to calculate the difference at group level between the start of therapy and 7 years of ERT. Patients’ individual responses over time were also evaluated. Results: Eleven males and six females started ERT at ages between 1.1 and 16.4 years (median 11.9 years); 82% of them carried the common c.‐32‐13T > G GAA gene variant on one allele. At group level, distance walked increased by 7.4 percentage points (p < 0.001) and QMFT scores increased by 9.2 percentage points (p = 0.006). Muscle strength scores seemed to remain stable. Results on lung function were more variable. Patients’ individual data show that the proportion of patients who stabilized or improved during treatment ranged between 56 and 69% for lung function outcomes and between 71 and 93% for muscle strength and muscle function outcomes. Conclusions: We report a positive effect of ERT in patients with childhood Pompe disease at group level. For some patients, new or personalized treatments should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given their clinical heterogeneity, finding effective treatments has been a challenge with the only approved therapy, ERT, creating secondary complications from increased survival.232”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [232]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526 · cited 1×
“Multiple testing correction was applied according to the Holm method (Holm 1979).”
MethodATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Quanjer, P. H., Stanojevic, S., Cole, T. J., Baur, X., Hall, G. L., Culver, B. H., Enright, P. L., Hankinson, J. L., Ip, M. S. M., Zheng, J., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00080312 · Cited by 5,919 · cited 1×
“…(FVC) was measured in sitting and supine positions according to European Respiratory Society and ATS guidelines, and was presented as a percentage of the predicted FVC, corrected for height, gender and ethnicity (American Thoracic Society/European Respiratory Society 2002; Quanjer et al 2012).”
MethodATS/ERS Statement on Respiratory Muscle Testing
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.166.4.518 · Cited by 2,841
Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease
Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W. L., Leslie, N., Levine, J., Spencer, C., McDonald, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000251268.41188.04 · Cited by 781 · cited 1×
“ERT has been shown to reverse the hypertrophic cardiomyopathy and increase survival in classic-infantile patients (Van den Hout et al 2000; Kishnani et al 2007).”
Backgroundvan der Ploeg, A. T., & Reuser, A. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61555-x · Cited by 756
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
van der Ploeg, A. T., Clemens, P. R., Corzo, D., Escolar, D. M., Florence, J., Groeneveld, G. J., Herson, S., Kishnani, P. S., Laforet, P., Lake, S. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909859 · Cited by 745 · cited 6×
“In addition, patient 16 was included in the international randomized controlled trial (van der Ploeg et al 2010).”
BackgroundResultInfluentialKishnani, P. S., Hwu, W.-L., Mandel, H., Nicolino, M., Yong, F., & Corzo, D. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.11.033 · Cited by 598 · cited 1×
“Without enzyme replacement therapy (ERT), these infants usually die within the first year of life (van den Hout et al 2003; Kishnani et al 2006).”
Backgroundvan den Hout, H. M. P., Hop, W., van Diggelen, O. P., Smeitink, J. A. M., Smit, G. P. A., Poll-The, B.-T. T., Bakker, H. D., Loonen, M. C. B., de Klerk, J. B. C., Reuser, A. J. J., et al. (2003) · Pediatrics · doi:10.1542/peds.112.2.332 · Cited by 555 · cited 1×
“Without enzyme replacement therapy (ERT), these infants usually die within the first year of life (van den Hout et al 2003; Kishnani et al 2006).”
BackgroundRecombinant human α-glucosidase from rabbit milk in Pompe patients
Van den Hout, H., Reuser, A. J., Vulto, A. G., Christa B Loonen, M., Cromme-Dijkhuis, A., & Van der Ploeg, A. T. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02533-2 · Cited by 330 · cited 1×
“ERT has been shown to reverse the hypertrophic cardiomyopathy and increase survival in classic-infantile patients (Van den Hout et al 2000; Kishnani et al 2007).”
BackgroundBeenakker, E. A. C., van der Hoeven, J. H., Fock, J. M., & Maurits, N. M. (2001) · Neuromuscular Disorders · doi:10.1016/s0960-8966(01)00193-6 · Cited by 305 · cited 2×
“HHD was presented as age and gender adjusted percentage predicted (Beenakker et al 2001); MRC as a percentage of the maximum score (the maximum score of 5 indicates normal strength for age).”
MethodOver idiopathische hypertrophie van het hart
Pompe, J. (1932) · Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank · Cited by 290
Strothotte, S., Strigl-Pill, N., Grunert, B., Kornblum, C., Eger, K., Wessig, C., Deschauer, M., Breunig, F., Glocker, F. X., Vielhaber, S., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5275-3 · Cited by 256 · cited 2×
“In adult patients, positive effects were also demonstrated on endurance, muscle strength, pulmonary function, and survival (Bembi et al 2010; Strothotte et al 2010; van der Ploeg et al 2010; Angelini et al 2012; de Vries et al 2012; Regnery et al 2012; van der Ploeg et al 2012; Anderson et al 2014;…”
BackgroundThe spectrum and diagnosis of acid maltase deficiency
Engel, A. G., Gomez, M. R., Seybold, M. E., & Lambert, E. H. (1973) · Neurology · doi:10.1212/wnl.23.1.95 · Cited by 255 · cited 1×
“The heart is rarely involved (Engel et al 1973; Laforet et al 2000; Slonim et al 2000; Van der Beek et al 2009; van der Beek et al 2011; Gungor and Reuser 2013).”
Enzyme replacement therapy in late‐onset Pompe's disease: A three‐year follow‐up
Winkel, L. P. F., Van den Hout, J. M. P., Kamphoven, J. H. J., Disseldorp, J. A. M., Remmerswaal, M., Arts, W. F. M., Loonen, M. C. B., Vulto, A. G., Van Doorn, P. A., De Jong, G., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20019 · Cited by 233 · cited 4×
“Supplemental Table 2 summarizes the results of eight publications that report on the outcomes of children treated with ERT (Winkel et al 2004; Rossi et al 2007; van Capelle et al 2008; Bembi et al 2010; van Capelle et al 2010; Ishigaki et al 2012; Deroma et al 2014; Porta et al 2015).”
BackgroundMethodInfluentialJuvenile and adult-onset acid maltase deficiency in France: Genotype–phenotype correlation
Laforêt, P., Nicolino, M., Eymard, B., Puech, J. P., Caillaud, C., Poenaru, L., & Fardeau, M. (2000) · Neurology · doi:10.1212/wnl.55.8.1122 · Cited by 216 · cited 1×
“The heart is rarely involved (Engel et al 1973; Laforet et al 2000; Slonim et al 2000; Van der Beek et al 2009; van der Beek et al 2011; Gungor and Reuser 2013).”
Reference values for the 6-minute walk test in healthy children and adolescents in Switzerland
Ulrich, S., Hildenbrand, F. F., Treder, U., Fischler, M., Keusch, S., Speich, R., & Fasnacht, M. (2013) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-13-49 · Cited by 191 · cited 1×
“The percentage of predicted meters walked (6MWT-PP) was calculated on the basis of gender-matched and age-matched healthy peers (Ulrich et al 2013).”
MethodEnzyme replacement therapy in late-onset Pompe disease: a systematic literature review
Toscano, A., & Schoser, B. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6636-x · Cited by 190 · cited 1×
“Studies on late-onset patients occasionally include children: a review from 2013 identified 27 children amongst 368 patients in 21 papers (Toscano and Schoser 2013).”
BackgroundClinical features of late‐onset Pompe disease: A prospective cohort study
Wokke, J. H. J., Escolar, D. M., Pestronk, A., Jaffe, K. M., Carter, G. T., van den Berg, L. H., Florence, J. M., Mayhew, J., Skrinar, A., Corzo, D., et al. (2008) · Muscle & Nerve · doi:10.1002/mus.21025 · Cited by 175 · cited 2×
“In untreated adult patients and children, FVC has been reported to decline between 1 pp. and 5.5 pp. per year (Wokke et al 2008; van Capelle et al 2010; van der Ploeg et al 2010; van der Beek et al 2011; de Vries et al 2012; van der Beek et al 2012).”
BackgroundResultInfluentialvan der Ploeg, A. T., Kruijshaar, M. E., Toscano, A., Laforêt, P., Angelini, C., Lachmann, R. H., Pascual Pascual, S. I., Roberts, M., Rösler, K., Stulnig, T., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13285 · Cited by 173 · cited 2×
“In adult patients, positive effects were also demonstrated on endurance, muscle strength, pulmonary function, and survival (Bembi et al 2010; Strothotte et al 2010; van der Ploeg et al 2010; Angelini et al 2012; de Vries et al 2012; Regnery et al 2012; van der Ploeg et al 2012; Anderson et al 2014; Stepien et al 2016;…”
BackgroundSelf-citationIdentification of two subtypes of infantile acid maltase deficiency
Slonim, A. E., Bulone, L., Ritz, S., Goldberg, T., Chen, A., & Martiniuk, F. (2000) · The Journal of Pediatrics · doi:10.1067/mpd.2000.107112 · Cited by 165 · cited 2×
“The heart is rarely involved (Engel et al 1973; Laforet et al 2000; Slonim et al 2000; Van der Beek et al 2009; van der Beek et al 2011; Gungor and Reuser 2013).”
Backgroundvan der Beek, N. A. M. E., de Vries, J. M., Hagemans, M. L. C., Hop, W. C. J., Kroos, M. A., Wokke, J. H. J., de Visser, M., van Engelen, B. G. M., Kuks, J. B. M., van der Kooi, A. J., et al. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-88 · Cited by 160 · cited 2×
“In untreated adult patients and children, FVC has been reported to decline between 1 pp. and 5.5 pp. per year (Wokke et al 2008; van Capelle et al 2010; van der Ploeg et al 2010; van der Beek et al 2011; de Vries et al 2012; van der Beek et al 2012).”
BackgroundResultInfluentialOpen-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa
van der Ploeg, A. T., Barohn, R. J., Carlson, L., Charrow, J., Clemens, P. R., Hopkin, R. J., Kishnani, P. S., Laforêt, P., Morgan, C. L., Nations, S., et al. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.09.015 · Cited by 137 · cited 1×
“…on endurance, muscle strength, pulmonary function, and survival (Bembi et al 2010; Strothotte et al 2010; van der Ploeg et al 2010; Angelini et al 2012; de Vries et al 2012; Regnery et al 2012; van der Ploeg et al 2012; Anderson et al 2014; Stepien et al 2016; Van Der Ploeg et al 2017).”
BackgroundThe Italian GSDII Group, Angelini, C. I., Semplicini, C., Ravaglia, S., Bembi, B., Servidei, S., Pegoraro, E., Moggio, M. G., Filosto, M., Sette, E., et al. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6293-5 · Cited by 134 · cited 2×
“…demonstrated on endurance, muscle strength, pulmonary function, and survival (Bembi et al 2010; Strothotte et al 2010; van der Ploeg et al 2010; Angelini et al 2012; de Vries et al 2012; Regnery et al 2012; van der Ploeg et al 2012; Anderson et al 2014; Stepien et al 2016; Van Der Ploeg et al…”
BackgroundRegnery, C., Kornblum, C., Hanisch, F., Vielhaber, S., Strigl‐Pill, N., Grunert, B., Müller‐Felber, W., Glocker, F. X., Spranger, M., Deschauer, M., et al. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9451-8 · Cited by 133
Respiratory insufficiency and limb muscle weakness in adults with Pompe’s disease
Pellegrini, N., Laforêt, P., Orlikowski, D., Pellegrini, M., Caillaud, C., Eymard, B., Raphael, J.-C., & Lofaso, F. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00020005 · Cited by 112 · cited 1×
“The poorer response with regard to lung function might be due to the involvement of the diaphragm (Pellegrini et al 2005; Prigent et al 2012; Gaeta et al 2013; Wens et al 2015; Mogalle et al 2016).”
Backgroundvan der Beek, N. A. M. E., van Capelle, C. I., Etten, K. I. V. D. V.-V., Hop, W. C. J., van den Berg, B., Reuser, A. J. J., van Doorn, P. A., van der Ploeg, A. T., & Stam, H. J. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.06.012 · Cited by 110 · cited 3×
“In untreated adult patients and children, FVC has been reported to decline between 1 pp. and 5.5 pp. per year (Wokke et al 2008; van Capelle et al 2010; van der Ploeg et al 2010; van der Beek et al 2011; de Vries et al 2012; van der Beek et al 2012).”
BackgroundResultInfluentialRate of disease progression during long-term follow-up of patients with late-onset Pompe disease
van der Beek, N. A. M. E., Hagemans, M. L. C., Reuser, A. J. J., Hop, W. C. J., van der Ploeg, A. T., van Doorn, P. A., & Wokke, J. H. J. (2008) · Neuromuscular Disorders · doi:10.1016/j.nmd.2008.11.007 · Cited by 109 · cited 1×
“The heart is rarely involved (Engel et al 1973; Laforet et al 2000; Slonim et al 2000; Van der Beek et al 2009; van der Beek et al 2011; Gungor and Reuser 2013).”
de Vries, J. M., van der Beek, N. A. M. E., Hop, W. C. J., Karstens, F., Wokke, J. H. J., de Visser, M., van Engelen, B. G. M., Kuks, J. B. M., van der Kooi, A. J., Notermans, N. C., et al. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-73 · Cited by 109 · cited 3×
“In untreated adult patients and children, FVC has been reported to decline between 1 pp. and 5.5 pp. per year (Wokke et al 2008; van Capelle et al 2010; van der Ploeg et al 2010; van der Beek et al 2011; de Vries et al 2012; van der Beek et al 2012).”
BackgroundInfluentialSelf-citationvan Capelle, C. I., Winkel, L. P. F., Hagemans, M. L. C., Shapira, S. K., Arts, W. F. M., van Doorn, P. A., Hop, W. C. J., Reuser, A. J. J., & van der Ploeg, A. T. (2008) · Neuromuscular Disorders · doi:10.1016/j.nmd.2008.04.009 · Cited by 99 · cited 3×
“Supplemental Table 2 summarizes the results of eight publications that report on the outcomes of children treated with ERT (Winkel et al 2004; Rossi et al 2007; van Capelle et al 2008; Bembi et al 2010; van Capelle et al 2010; Ishigaki et al 2012; Deroma et al 2014; Porta et al 2015).”
BackgroundMethodBembi, B., Pisa, F. E., Confalonieri, M., Ciana, G., Fiumara, A., Parini, R., Rigoldi, M., Moglia, A., Costa, A. C., Carlucci, A., et al. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9201-8 · Cited by 93 · cited 2×
“In adult patients, positive effects were also demonstrated on endurance, muscle strength, pulmonary function, and survival (Bembi et al 2010; Strothotte et al 2010; van der Ploeg et al 2010; Angelini et al 2012; de Vries et al 2012; Regnery et al 2012; van der Ploeg et al 2012; Anderson et al 2014;…”
BackgroundHow to describe the clinical spectrum in Pompe disease?
Güngör, D., & Reuser, A. J. J. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35662 · Cited by 84 · cited 3×
“The heart is rarely involved (Engel et al 1973; Laforet et al 2000; Slonim et al 2000; Van der Beek et al 2009; van der Beek et al 2011; Gungor and Reuser 2013).”
BackgroundChildhood Pompe disease: clinical spectrum and genotype in 31 patients
van Capelle, C. I., van der Meijden, J. C., van den Hout, J. M. P., Jaeken, J., Baethmann, M., Voït, T., Kroos, M. A., Derks, T. G. J., Rubio‐Gozalbo, M. E., Willemsen, M. A. A. P., et al. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0442-y · Cited by 80 · cited 2×
“Our recent cross-sectional study of 31 untreated children with non-classic presentations showed that 25% needed a wheelchair during childhood, 48% had decreased pulmonary function, 25% needed respiratory support, and two died before reaching adulthood (van Capelle et al 2016).”
BackgroundMethodvan Capelle, C. I., van der Beek, N. A. M. E., de Vries, J. M., van Doorn, P. A., Duivenvoorden, H. J., Leshner, R. T., Hagemans, M. L. C., & van der Ploeg, A. T. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9388-3 · Cited by 71
Genotype-phenotype correlation in Pompe disease, a step forward
Filippi, P. D., Saeidi, K., Ravaglia, S., Dardis, A., Angelini, C. I., Mongini, T., Morandi, L. O., Moggio, M. G., Muzio, A. D., Filosto, M., et al. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0102-z · Cited by 70 · cited 1×
“Other factors that could be involved in the response to ERT are the type of mutation in the GAA gene, genetic background factors such as the ACE polymorphisms (Ravaglia et al 2012; De Filippi et al 2014; Baek et al 2016), or antibodies against ERT with alglucosidase alfa.”
BackgroundAnderson, L. J., Henley, W., Wyatt, K. M., Nikolaou, V., Waldek, S., Hughes, D. A., Lachmann, R., & Logan, S. (2014) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-014-9728-1 · Cited by 66 · cited 1×
“…on endurance, muscle strength, pulmonary function, and survival (Bembi et al 2010; Strothotte et al 2010; van der Ploeg et al 2010; Angelini et al 2012; de Vries et al 2012; Regnery et al 2012; van der Ploeg et al 2012; Anderson et al 2014; Stepien et al 2016; Van Der Ploeg et al 2017).”
BackgroundGaeta, M., Barca, E., Ruggeri, P., Minutoli, F., Rodolico, C., Mazziotti, S., Milardi, D., Musumeci, O., & Toscano, A. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.06.023 · Cited by 63 · cited 1×
“The poorer response with regard to lung function might be due to the involvement of the diaphragm (Pellegrini et al 2005; Prigent et al 2012; Gaeta et al 2013; Wens et al 2015; Mogalle et al 2016).”
BackgroundEffect of enzyme therapy in juvenile patients with Pompe disease: A three-year open-label study
van Capelle, C. I., van der Beek, N. A. M. E., Hagemans, M. L. C., Arts, W. F. M., Hop, W. C. J., Lee, P., Jaeken, J., Frohn-Mulder, I. M. E., Merkus, P. J. F. M., Corzo, D., et al. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.07.277 · Cited by 59 · cited 8×
“Throughout follow-up, patients 3, 5, 11, 12, and 15 performed a running variant rather than the standard 6MWT (van Capelle et al 2010).”
BackgroundMethodResultInfluentialPompe disease in adulthood: effects of antibody formation on enzyme replacement therapy
de Vries, J. M., Kuperus, E., Hoogeveen‐Westerveld, M., Kroos, M. A., Wens, S. C. A., Stok, M., van der Beek, N. A. M. E., Kruijshaar, M. E., Rizopoulos, D., van Doorn, P. A., et al. (2016) · Genetics in Medicine · doi:10.1038/gim.2016.70 · Cited by 58 · cited 1×
“It was also shown in adult patients that the vast majority had low antibody titers, while a counteracting effect was demonstrated only in incidental cases (de Vries et al 2017).”
BackgroundSelf-citationRossi, M., Parenti, G., Casa, R. D., Romano, A., Mansi, G., Agovino, T., Rosapepe, F., Vosa, C., GIUDICE, E. D., & Andria, G. (2007) · Journal of Child Neurology · doi:10.1177/0883073807302598 · Cited by 55 · cited 1×
“Supplemental Table 2 summarizes the results of eight publications that report on the outcomes of children treated with ERT (Winkel et al 2004; Rossi et al 2007; van Capelle et al 2008; Bembi et al 2010; van Capelle et al 2010; Ishigaki et al 2012; Deroma et al 2014; Porta et al 2015).”
BackgroundSupine volume drop and diaphragmatic function in adults with Pompe disease: Table 1–
Prigent, H., Orlikowski, D., Laforêt, P., Letilly, N., Falaize, L., Pellegrini, N., Annane, D., Raphaël, J., & Lofaso, F. (2012) · European Respiratory Journal · doi:10.1183/09031936.00169011 · Cited by 54 · cited 1×
“The poorer response with regard to lung function might be due to the involvement of the diaphragm (Pellegrini et al 2005; Prigent et al 2012; Gaeta et al 2013; Wens et al 2015; Mogalle et al 2016).”
BackgroundStępień, K. M., Hendriksz, C. J., Roberts, M., & Sharma, R. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.01.013 · Cited by 53 · cited 1×
“…on endurance, muscle strength, pulmonary function, and survival (Bembi et al 2010; Strothotte et al 2010; van der Ploeg et al 2010; Angelini et al 2012; de Vries et al 2012; Regnery et al 2012; van der Ploeg et al 2012; Anderson et al 2014; Stepien et al 2016; Van Der Ploeg et al 2017).”
BackgroundLung MRI and impairment of diaphragmatic function in Pompe disease
Wens, S. C. A., Ciet, P., Perez‐Rovira, A., Logie, K. M., Salamon, E. R., Wielopolski, P. A., de Bruijne, M., Kruijshaar, M. E., Tiddens, H. A. W. M., van Doorn, P. A., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0058-3 · Cited by 51 · cited 1×
“The poorer response with regard to lung function might be due to the involvement of the diaphragm (Pellegrini et al 2005; Prigent et al 2012; Gaeta et al 2013; Wens et al 2015; Mogalle et al 2016).”
BackgroundSelf-citationQuantification of Diaphragm Mechanics in Pompe Disease Using Dynamic 3D MRI
Mogalle, K., Perez‐Rovira, A., Ciet, P., Wens, S. C. A., van Doorn, P. A., Tiddens, H. A. W. M., van der Ploeg, A. T., & de Bruijne, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158912 · Cited by 42 · cited 1×
“The poorer response with regard to lung function might be due to the involvement of the diaphragm (Pellegrini et al 2005; Prigent et al 2012; Gaeta et al 2013; Wens et al 2015; Mogalle et al 2016).”
BackgroundEnzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study
Deroma, L., Guerra, M., Sechi, A., Ciana, G., Cisilino, G., Dardis, A., & Bembi, B. (2014) · European Journal of Pediatrics · doi:10.1007/s00431-013-2258-2 · Cited by 20 · cited 1×
“Supplemental Table 2 summarizes the results of eight publications that report on the outcomes of children treated with ERT (Winkel et al 2004; Rossi et al 2007; van Capelle et al 2008; Bembi et al 2010; van Capelle et al 2010; Ishigaki et al 2012; Deroma et al 2014; Porta et al 2015).”
BackgroundRavaglia, S., Filippi, P. D., Pichiecchio, A., Ponzio, M., Saeidi, K., Poloni, G., Bini, P., & Danesino, C. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.05.016 · Cited by 17 · cited 1×
“Other factors that could be involved in the response to ERT are the type of mutation in the GAA gene, genetic background factors such as the ACE polymorphisms (Ravaglia et al 2012; De Filippi et al 2014; Baek et al 2016), or antibodies against ERT with alglucosidase alfa.”
BackgroundIshigaki, K., Murakami, T., Nakanishi, T., Oda, E., Sato, T., & Ōsawa, M. (2011) · Brain and Development · doi:10.1016/j.braindev.2011.05.004 · Cited by 13 · cited 1×
“Supplemental Table 2 summarizes the results of eight publications that report on the outcomes of children treated with ERT (Winkel et al 2004; Rossi et al 2007; van Capelle et al 2008; Bembi et al 2010; van Capelle et al 2010; Ishigaki et al 2012; Deroma et al 2014; Porta et al 2015).”
BackgroundBaek, R. C., Palmer, R., Pomponio, R. J., Lu, Y., Ma, X., & McVie-Wylie, A. J. (2016) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2016.07.005 · Cited by 11 · cited 1×
“Other factors that could be involved in the response to ERT are the type of mutation in the GAA gene, genetic background factors such as the ACE polymorphisms (Ravaglia et al 2012; De Filippi et al 2014; Baek et al 2016), or antibodies against ERT with alglucosidase alfa.”
BackgroundPlaying competitive basketball in face of late‐onset pompe disease
Porta, F., Pagliardini, V., Roasio, L., Biamino, E., & Spada, M. (2014) · Muscle & Nerve · doi:10.1002/mus.24522 · Cited by 3
Research works printed but not linked: 2
- 1978, Aids to the Examination of the Peripheral Nervous System, Memorandum No. 45
- Core Team R, 2015, R Foundation for Statistical Computing
Cited by
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
Neufeld, E. F. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001353 · Cited by 900
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Given their clinical heterogeneity, finding effective treatments has been a challenge with the only approved therapy, ERT, creating secondary complications from increased survival.(232) As the prevalence of these disorders increases with the advent of newborn screening, new therapeutic interventions, such as gene repl…”
BackgroundSemplicini, C., Antonio, M. D., Taouagh, N., Béhin, A., Bouhour, F., Echaniz‐Laguna, A., Magot, A., Nadaj‐Pakleza, A., Orlikowski, D., Sacconi, S., et al. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12272 · Cited by 63
“The prognosis of classical infantile Pompe disease has been considerably modified by ERT, administered intravenously with dosages ranging from 20 mg/kg/eo week to 40 mg/kg/week.(11,12) In the adult form, a randomized, double-blind, placebo-controlled trial (LOTS), conducted in 90 patients over an 18-month period, show…”
BackgroundPompe disease gene therapy: neural manifestations require consideration of CNS directed therapy
Byrne, B. J., Fuller, D. D., Smith, B. K., Clement, N., Coleman, K., Cleaver, B., Vaught, L., Falk, D. J., McCall, A., & Corti, M. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.56 · Cited by 51
Metadata
- Authors
- van der Meijden, J. C., Kruijshaar, M. E., Harlaar, L., Rizopoulos, D., van der Beek, N. A. M. E., & van der Ploeg, A. T.
- Affiliations
- Center for Lysosomal and Metabolic Diseases, Department of Pediatrics Erasmus MC University Medical Center Wytemaweg 80 Rotterdam 3015 CN The Netherlands
- Erasmus MC (NL)
- Center for Lysosomal and Metabolic Diseases, Department of Neurology Erasmus MC University Medical Center Rotterdam the Netherlands
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2018-03-19
- Volume
- 41
- Issue
- 6
- Pages
- 1205-1214
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- PMC
- PMC6326992
- OpenAlex
- W2789403551
- Cited by
- 37
- References
- 50
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 4
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Journal of Inherited Metabolic Disease (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Funders
- University Medical Center Rotterdam
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- Pompe disease, enzyme replacement therapy, muscle function, muscle strength, lung function, long-term follow-up, metabolic myopathies
- MeSH terms
- Walk Test, Adolescent, alpha-Glucosidases, Animals, Child, Child, Preschool, Female, Follow-Up Studies, Glycogen Storage Disease Type II, Humans, Infant, Male, Prospective Studies, Rabbits, Respiratory Function Tests, Linear Models, Treatment Outcome, Internationality, Muscle Strength, Enzyme Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.